Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Assists AstraZeneca in its Sale of Sular to First Horizon Pharmaceutical

February 14, 2002

February 14, 2002 - Washington, D.C. - Covington & Burling advised AstraZeneca (NYSE: AZN) in its sale of US distribution rights for Sular® (nisoldipine) to First Horizon Pharmaceutical Corp. (Nasdaq: FHRX) in a deal valued at up to $175 million.

Sular, which is manufactured by Bayer AG, is a once-a-day treatment for high blood pressure (hypertension). Sular had U.S. net sales of approximately $46 million in 2001.

Assisting AstraZeneca on the transaction were John Hurvitz, Ed Dixon, Marianna Horton and Ann Eirich of Covington & Burling.

For more information, please contact John A. Hurvitz, JHurvitz@cov.com, 202.662.5319 or Noël Decker, ndecker@cov.com, 202.662.6361.

Share this article: